Prediction of Low Side-Effect Repurposed Drug Compound For Systems Treatment of Colorectal Cancer

来源 :第八届海峡两岸生物学启发的理论科学问题研讨会(BITS8) | 被引量 : 0次 | 上传用户:ltxiong
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
After 40 years of “War on Cancer”,progress in reducing the overall cancer mortality rate has been disappointing.At the same time,many previously thought successful drugs have been withdrawn,mostly due to side-effect issues.Cancer is a disease caused by a breakdown of large parts of the cellular system (as well as higher systems) in the tumor,not just of the failure of one or two of its biological functions.Here,we used a systems approach to design optimal drug compounds for the purpose of reprogramming the tumor from an advanced state to less advanced state.We filtered out eight cancer related functional gene sets from cohort gene expression microarray data and applied the gene sets to the Connectivity Map to identify repurposed,intra-cellular side-effect free,candidate drug compounds for systems treatment of colonic adenoma.About a dozen drug compounds were identified.The top beneficial drug,GW-8510,a CDK2 inhibitor used as an adjuvant agent that protects hair-loss in chemotherapy,was highly enriched in seven cancer functional modules.Inversely,thapsigargin,known as an anticancer agent targeting endoplasmic reticulum ATPase,was identified to adversely affects several cancer functions including cancer signaling,cell proliferation,and transcription while strongly benefits apoptosis.This coincides with three previous reports that thapsigargin was a tumor promoter.Validation of these results in cell model experiments is under way.
其他文献
会议
会议
会议
会议
会议
会议
会议
会议
会议
会议